[
    {
        "_id": "V000001",
        "pmid": 30311408,
        "biomarkerId": "B000000",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2010.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Protein extraction and western blot",
                "Immunohistochemistry",
                "TCGA, CGGA, Rembrant and GSE16011 data analysis",
                "ROC curve",
                "PCA",
                "Microenvironment cell populations\u2010counter (MCP\u2010counter)",
                "Gene ontology analysis",
                "Gene set enrichment analysis",
                "Gene set variation analysis",
                "Kaplan-Meier method",
                "Log-rank test",
                "ANOVA",
                "Tukey post test"
            ],
            "results": [
                "CAVIN1 expression was elevated in GBM compared with that in low\u2010grade glioma and nontumor brain samples and was correlated with unfavorable outcomes in glioma patients",
                "CAVIN1 could serve as an independent predictive factor for progressive malignancy in GBM",
                "CAVIN1 was associated with disrupted angiogenesis and immune response in the tumor microenvironment of GBM"
            ],
            "conclusions": [
                "Identified CAVIN1 as a prognostic biomarker and potential target for developing novel therapeutic strategies against GBM"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000002",
        "pmid": 30290990,
        "biomarkerId": "B000001",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Meta-analysis of PubMed, Web of Science and Embase databases"
            ],
            "results": [
                "Pooled analyses showed that low miR-139 expression was related to worse OS (HR=\u202f2.27) in solid tumors, including HCC and GBM, consisting with the results of TCGA",
                "However, results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon",
                "For CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results",
                "The results of 27 microarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues compared to adjacent non-tumor tissues or healthy tissues",
                "Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR\u202f=\u202f3.57)",
                "Combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR\u202f=\u202f1.50), gender (pooled OR\u202f=\u202f0.92), tumor size (pooled OR\u202f=\u202f1.59), late tumor-node-metastasis stage (pooled OR\u202f=\u202f1.63)and lymph-node-metastasis (pooled OR\u202f=\u202f0.66)"
            ],
            "conclusions": [
                "Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker",
                "Its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "GEO and TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000003",
        "pmid": 30279739,
        "biomarkerId": "B000002",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2007.0,
        "region": [
            "Portugal",
            "France",
            "Brazil"
        ],
        "research": {
            "methods": [
                "TCGA data analysis",
                "Immunohistochemistry",
                "WNT6 silencing by shRNA in GBM cells",
                "WNT6 overexpression in GBM cells",
                "Immunofluorescence",
                "Cell viability assays",
                "Cell proliferation and cell migration",
                "Assessment of cell death and cell invasion",
                "Colony formation assay",
                "Cell viability assay under stem cell conditions",
                "Neurosphere formation assay",
                "Limiting dilution assay",
                "Stereotactic orthotopic xenograft model",
                "Human phospho-kinase antibody array",
                "Western blot",
                "TCF/LEF reporter assay",
                "Gene set enrichment analysis",
                "ANOVA",
                "Sidak's test",
                "Tukey's test",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "WNT6 is significantly overexpressed in GBMs, as compared to lower-grade gliomas and normal brain, at mRNA and protein levels",
                "Functionally, WNT6 increases typical oncogenic activities in GBM cells, including viability, proliferation, glioma stem cell capacity, invasion, migration, and resistance to temozolomide chemotherapy",
                "Concordantly, in in vivo orthotopic GBM mice models, using both overexpressing and silencing models, WNT6 expression was associated with shorter overall survival, and increased features of tumor aggressiveness",
                "Mechanistically, WNT6 contributes to activate typical oncogenic pathways, including Src and STAT, which intertwined with the WNT pathway may be critical effectors of WNT6-associated aggressiveness in GBM",
                "Clinically, WNT6 is established as an independent prognostic biomarker of shorter survival in GBM patients from several independent cohorts"
            ],
            "conclusions": [
                "Findings establish WNT6 as a novel oncogene in GBM, opening opportunities to develop more rational therapies to treat this highly aggressive tumor"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000004",
        "pmid": 30277538,
        "biomarkerId": "B00001C",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "Germany"
        ],
        "research": {
            "methods": [
                "Open-label, multicenter, phase I/IIa umbrella trial for patients with newly diagnosed isocitrate dehydrogenase (IDH) wildtype glioblastoma without MGMT promoter hypermethylation",
                "Neuropathological diagnostics",
                "Molecular diagnostics and bioinformatic evaluation",
                "Startification for treatment in 5 subtrials",
                "Randomization between subtrials",
                "Bayesian criteia for toxicity",
                "PFS calculation"
            ],
            "results": [
                "Molecular diagnostics and bioinformatic evaluation are performed within 4 weeks, allowing a timely initiation of postoperative treatment",
                "Stratification for treatment takes place in 5 subtrials, including alectinib, idasanutlin, palbociclib, vismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration",
                "Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept (APG101) and the standard of care, TMZ",
                "For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity",
                "In the phase II trials, progression-free survival at 6 months is used as endpoint for efficacy"
            ],
            "conclusions": [
                "Molecularly informed trials may provide the basis for the development of predictive biomarkers and help to understand and select patient subgroups who will benefit"
            ]
        },
        "application": {
            "validated": null,
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": "Yes",
            "therapeutic": "Yes"
        },
        "clinical": {
            "relevance": "MGMT promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management",
            "implication": "Use in companion diagnostics and predicting patient outcome",
            "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair;If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy"
        },
        "comments": null
    },
    {
        "_id": "V000005",
        "pmid": 30181543,
        "biomarkerId": "B000004",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Global pathway network",
                "Co-expression network",
                "Directed random walk algorithm",
                "Reweighted RSF model (RRSF)",
                "Breiman-Cutler permutation VIMP",
                "Cox PH method",
                "Kaplan-Meier curves",
                "Log-rank test",
                "Gene Ontology functional enrichment analysis"
            ],
            "results": [
                "RRSF predicted survival outcomes of GBM patients with higher accuracy than RSF",
                "RRSF identified a two-gene signaturewhich showed robust prognostic values and had biological relevance to the development of GBM"
            ],
            "conclusions": [
                "Study showed that, by integrating gene interaction information, RRSF could yield better predictive performance based not only on mRNA expression data (GBM as an example)"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000006",
        "pmid": 30146921,
        "biomarkerId": "B000005",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "India"
        ],
        "research": {
            "methods": [
                "RT-PCR",
                "Western Blot",
                "Immunohistochemistry",
                "Kaplan-Meier method",
                "Log-rank test"
            ],
            "results": [
                "Nck1 RNA and protein was upregulated significantly in high grade tissues as compared to low grade and control tissue samples",
                "Logrank test and Kaplan-Meier analysis signified the use of Nck1 as independent prognostic marker for astrocytoma progression and its expression levels were correlated with poor survival in surgically resected human tissue samples (Chi square\u2009=\u200910.7, p\u2009=\u20090.001)",
                "GBM was noticed to be predominant at frontal and temporal lobe"
            ],
            "conclusions": [
                "On account of it's over expression, Nck1 appears as possible biomarker for astrocytoma progression and may serve as an important therapeutic target",
                "Prominent origin of GBM at frontal and temporal lobe suggests possible involvement of tissue specific developmental or transcriptional factors in origin of tumors"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000007",
        "pmid": 30132538,
        "biomarkerId": "B000006",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000008",
        "pmid": 30132538,
        "biomarkerId": "B000007",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000009",
        "pmid": 30132538,
        "biomarkerId": "B000008",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00000A",
        "pmid": 30132538,
        "biomarkerId": "B000009",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00000B",
        "pmid": 30132538,
        "biomarkerId": "B00000A",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00000C",
        "pmid": 30132538,
        "biomarkerId": "B00000B",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00000D",
        "pmid": 30132538,
        "biomarkerId": "B00000C",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Differential gene expression analysis",
                "Gene Ontology and pathway enrichment analysis",
                "Integration of protein-protein interaction"
            ],
            "results": [
                "In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes",
                "After verification, the top four genes RANBP17, ZNF734, NLRP2 and GPR1 were identified as prognostic biomarkers for GBM",
                "The top four prognostic genes affected by sex were also identified and were as follows: CCDC81, NLRP2, SH3RF1 and TM7SF4"
            ],
            "conclusions": [
                "The identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00000E",
        "pmid": 30129426,
        "biomarkerId": "B00000D",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 18.0,
            "max": 70.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Germany"
        ],
        "research": {
            "methods": [
                "Immunoblot",
                "Immunohistochemistry",
                "Univariate survival analysis"
            ],
            "results": [
                "In this retrospective analysis of treatment-na\u00efve samples of the OSAG 101-BSA-05 trial cohort, EGFR signaling activity markers phosphorylated PRAS40 and phosphorylated ribosomal protein S6 are identified as predictive markers for treatment efficacy of the EGFR-blocking antibody nimotuzumab in MGMT promoter unmethylated GBs"
            ],
            "conclusions": [
                "Study report markers for the selection of patients that might benefit from the EGFR-blocking antibody nimotuzumab",
                "Results constitute a basis for further investigation of nimotuzumab or other EGFR- and mTOR-inhibitors in selected patient cohorts using the reported criteria as candidate predictive biomarkers"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": "Potential patient cohort selector",
            "implication": "Potential method to successfully divide patient cohorts for nimotuzumab treatment",
            "treatment": "Could lead to new method of defining patient cohorts for EGFR target treatment studies"
        },
        "comments": null
    },
    {
        "_id": "V00000F",
        "pmid": 30129426,
        "biomarkerId": "B00000E",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 18.0,
            "max": 70.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Germany"
        ],
        "research": {
            "methods": [
                "Immunoblot",
                "Immunohistochemistry",
                "Univariate survival analysis"
            ],
            "results": [
                "In this retrospective analysis of treatment-na\u00efve samples of the OSAG 101-BSA-05 trial cohort, EGFR signaling activity markers phosphorylated PRAS40 and phosphorylated ribosomal protein S6 are identified as predictive markers for treatment efficacy of the EGFR-blocking antibody nimotuzumab in MGMT promoter unmethylated GBs"
            ],
            "conclusions": [
                "Study report markers for the selection of patients that might benefit from the EGFR-blocking antibody nimotuzumab",
                "Results constitute a basis for further investigation of nimotuzumab or other EGFR- and mTOR-inhibitors in selected patient cohorts using the reported criteria as candidate predictive biomarkers"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": "Potential patient cohort selector",
            "implication": "Potential method to successfully divide patient cohorts for nimotuzumab treatment",
            "treatment": "Could lead to new method of defining patient cohorts for EGFR target treatment studies"
        },
        "comments": null
    },
    {
        "_id": "V000010",
        "pmid": 30096248,
        "biomarkerId": "B00000F",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 45.77,
            "max": 59.38,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Egypt",
            "Saudi Arabia"
        ],
        "research": {
            "methods": [
                "Genetic profiling of miR-326 and H19",
                "Methylation specific PCR",
                "Chi-square test",
                "Kruskal-Wallis test",
                "Mann-Whitney U test",
                "ROC curve analysis",
                "Log-rank test",
                "PCA"
            ],
            "results": [
                "Relative expression levels of miR-326 were not found to be significantly altered in GBM patients",
                "H19 was consistently over-expressed in all GBM patients, and was correlated with poorer overall survival (OS) and progression-free survival (PFS)"
            ],
            "conclusions": [
                "Despite our in silico data, expression level analysis for both lncRNA and miRNA were not significantly correlated",
                "Data suggest a role for H19 in the pathogenesis of GBM and could be a potential prognostic biomarker for GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000011",
        "pmid": 30080989,
        "biomarkerId": "B000010",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2007.0,
        "region": [
            "Italy"
        ],
        "research": {
            "methods": [
                "X-ray irradiation",
                "Establishment of radioresistant cel lines",
                "Clonogenic assay",
                "Western blot",
                "Telomerase activity assay",
                "Real-time PCR",
                "Kaplan-Meier curves",
                "Pearson test"
            ],
            "results": [
                "ACD expression appeared strongly upregulated in higher grade gliomas, and its expression was significantly correlated to grading and poor prognosis",
                "In glioma cell lines, ACD expression pattern was similar to those observed in glioma tissues",
                "In irradiated cells, ACD expression was increased in an ionizing radiation dose-dependent manner",
                "A higher expression of ACD was observed in the radioresistant clones than parental cells",
                "Silencing of ACD led to the enhanced radiation sensitivity, decreased telomerase activity and cyclin D1 expression, reduced expression of BIRC1, and finally to the upregulation of caspase-3"
            ],
            "conclusions": [
                "Study represents the first report, which demonstrated the expression pattern of ACD in gliomas and its prognostic value",
                "Results suggested that ACD is involved in glioblastoma radioresistance, likely through the modulation of telomerase activity, proliferation, and apoptosis",
                "ACD might represent a potential molecular biomarker and a novel therapeutic target in glioblastoma"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000012",
        "pmid": 30069164,
        "biomarkerId": "B000011",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 43.0,
                "under": 166.0,
                "over": 143.0
            }
        },
        "gender": {
            "male": 143.0,
            "female": 143.0,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Pyrosequencing",
                "Gene ontology and gene set enrichment analysis",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "Expression profiling identified 169 aberrantly expressed antisense lncRNAs between lower grade glioma (LGG) (grade II and III) and GBM, 113 antisense lncRNAs between LGG IDH-wt and IDH-mut samples, and 70 antisense lncRNAs between GBM IDH-wt and IDH-mut samples, respectively",
                "Three antisense lncRNAs (WDFY3-AS2, MCM3AP-AS1 and LBX2-AS1) were significantly associated with prognosis and malignant progression of patients",
                "WDFY3-AS2, the top one of downregulated antisense lncRNAs in GBM with fold change of 0.44, showed specific decreased expression in classical, mesenchymal, LGG IDH-wt, GBM IDH-wt or MGMT promoter unmethylated stratified patients"
            ],
            "conclusions": [
                "Findings provided convincing evidence that WDFY3-AS2 is a novel valuable prognostic biomarker for diffuse glioma"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000013",
        "pmid": 30053126,
        "biomarkerId": "B000012",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "USA",
            "Republic of Korea"
        ],
        "research": {
            "methods": [
                "Univariate Cox regression",
                "Gene set enrichment analysis",
                "Log-rank test",
                "Kaplan-Meier curves"
            ],
            "results": [
                "Cell cycle/repair/JAK-STAT pathways and TP53 mutation are prognostic in Classical GBM",
                "PI3K/MAPK/WNT pathways and PIK3R1/PCLO mutations are prognostic in Mesenchymal GBM",
                "6p loss and 10q loss are prognostic in Classical and G-CIMP GBM, respectively"
            ],
            "conclusions": [
                "Subtype-specific alterations have promising potentials as new prognostic biomarkers and therapeutic targets combined with surrogate markers of GBM subtypes",
                "Considering the small number of events, the results of copy number alterations and mutations require further validations"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "Public data sets",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000014",
        "pmid": 30053126,
        "biomarkerId": "B000013",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "USA",
            "Republic of Korea"
        ],
        "research": {
            "methods": [
                "Univariate Cox regression",
                "Gene set enrichment analysis",
                "Log-rank test",
                "Kaplan-Meier curves"
            ],
            "results": [
                "Cell cycle/repair/JAK-STAT pathways and TP53 mutation are prognostic in Classical GBM",
                "PI3K/MAPK/WNT pathways and PIK3R1/PCLO mutations are prognostic in Mesenchymal GBM",
                "6p loss and 10q loss are prognostic in Classical and G-CIMP GBM, respectively"
            ],
            "conclusions": [
                "Subtype-specific alterations have promising potentials as new prognostic biomarkers and therapeutic targets combined with surrogate markers of GBM subtypes",
                "Considering the small number of events, the results of copy number alterations and mutations require further validations"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "Public data sets",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000015",
        "pmid": 30053126,
        "biomarkerId": "B000014",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "USA",
            "Republic of Korea"
        ],
        "research": {
            "methods": [
                "Univariate Cox regression",
                "Gene set enrichment analysis",
                "Log-rank test",
                "Kaplan-Meier curves"
            ],
            "results": [
                "Cell cycle/repair/JAK-STAT pathways and TP53 mutation are prognostic in Classical GBM",
                "PI3K/MAPK/WNT pathways and PIK3R1/PCLO mutations are prognostic in Mesenchymal GBM",
                "6p loss and 10q loss are prognostic in Classical and G-CIMP GBM, respectively"
            ],
            "conclusions": [
                "Subtype-specific alterations have promising potentials as new prognostic biomarkers and therapeutic targets combined with surrogate markers of GBM subtypes",
                "Considering the small number of events, the results of copy number alterations and mutations require further validations"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "Public data sets",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000016",
        "pmid": 30038102,
        "biomarkerId": "B00001C",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 20.0,
            "max": 75.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2007.0,
        "region": [
            "India"
        ],
        "research": {
            "methods": [
                "Histology",
                "Immunohistochemistry",
                "Methylation-specific PCR",
                "Fluorescence in-situ hybridization",
                "Fisher's exact test",
                "Logistic regression analysis",
                "Multivariate regression"
            ],
            "results": [
                "MGMT gene promoter methylation was identified in 49.2% (66/134) GBMs, and was significantly associated with IDH1R132H mutation (14/66) and ATRX loss (15/66)",
                "Confluent necrosis was found to be significantly associated with MGMT unmethylation status",
                "Necrosis emerged as a single independent predictor (odds ratio= 2.5) of MGMT unmethylation status among all the parameters studied"
            ],
            "conclusions": [
                "The frequency of MGMT promoter methylation in GBMs was 49.2%, which was significantly associated with IDHR132H mutation and ATRX loss",
                "In addition, the presence of confluent necrosis was significantly associated with MGMT unmethylation and was found to be an independent predictor of the same"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "It is a validation study",
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": "Yes",
            "therapeutic": "Yes"
        },
        "clinical": {
            "relevance": "MGMT promoter methylation has been firmly established as a biomarker in patients diagnosed with gliomas, for both clinical trials and routine clinical management.",
            "implication": "Use in companion diagnostics and predicting patient outcome",
            "treatment": "Methylation status of the MGMT gene is crucial to promoting DNA repair;If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy"
        },
        "comments": null
    },
    {
        "_id": "V000017",
        "pmid": 30015879,
        "biomarkerId": "B000016",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 60.0,
                "under": 23.0,
                "over": 37.0
            }
        },
        "gender": {
            "male": 37.0,
            "female": 37.0,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "CCK8 assay",
                "RT-PCR",
                "Apoptosis assay",
                "In vitro migration and invasion assay",
                "In vivo assay",
                "Luciferase reprter assay",
                "Kaplan-Meier method",
                "Log-rank test",
                "ANOVA",
                "Tukey's test",
                "ROC curve analysis"
            ],
            "results": [
                "miR-500a-5p was highly expressed in malignant GBM tissues and cell lines",
                "Overexpression of miR-500a-5p promoted GBM cell proliferation, migration and invasion in vitro",
                "Knockdown of miR-500a-5p accelerated cell apoptosis",
                "miR-500a-5p inhibition significantly impaired tumor growth in vivo",
                "miR-500a-5p directly binds the 3\u2032-untranslated region of chromodomain helicase DNA binding protein 5 (CHD5) mRNA",
                "miR-500a-5p markedly inhibited CHD5 expression in glioblastoma cells",
                "CHD5 was downregulated in glioblastoma tissues, and the expression levels of miR-500a-5p and CHD5 were inversely correlated",
                "Knockdown of CHD5 restored the inhibition of cell proliferation and migration triggered by miR-500a-5p silence"
            ],
            "conclusions": [
                "Demonstrated that miR-500a-5p can serve as a novel biomarker for the diagnosis and prognosis of GBM patients",
                "Taken together, the results of the present study indicated that miR-500a-5p may have promoted glioblastoma development and progression by targeting CHD5"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000018",
        "pmid": 30009411,
        "biomarkerId": "B000017",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 22.0,
            "max": 83.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "France"
        ],
        "research": {
            "methods": [
                "Tissue microarray",
                "Immunohistochemistry",
                "Cell viability assay",
                "RT-qPCR",
                "Cell fractionation",
                "Western blot",
                "Immunofluorescence",
                "Transcriptome analysis",
                "Kaplan-Meier method",
                "Kruskal-Wallis test",
                "Mann-Whitney test",
                "Mantel-Cox log rank or Cox regression test"
            ],
            "results": [
                "For the first time that YAP1 expression is related to glioma molecular subtypes and is associated with poor patient outcome",
                "YAP1 may have prognostic significance for predicting patient survival, especially in low-grade gliomas",
                "YAP1 was activated and that it controlled cell proliferation",
                "Lower expression of YAP1 found in the proneural GBM subtype",
                "Overexpression of YAP1 was sufficient to inhibit the OLIG2 proneural marker, suggesting its involvement in maintenance of the GBM phenotype"
            ],
            "conclusions": [
                "Results showed that YAP1 could be a relevant prognostic biomarker and a potential therapeutic target in glioma"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000019",
        "pmid": 29995176,
        "biomarkerId": "B000018",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Flow cytometry",
                "qRT-PCR",
                "Cell proliferation assay",
                "Immunohistochemistry",
                "Western blot",
                "Subcutaneous xenograft model",
                "In silico nalysis of TCGA data",
                "Paired t-test",
                "Chi-square test",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "NUSAP1 was significantly up-regulated in GBM tissues compared with adult non-tumor brain tissues both in a validated cohort and a TCGA cohort",
                "Patients with high NUSAP1 expression had significantly lower OS",
                "In the TCGA cohort, NUSAP1 expression was relatively lower in GBM patients within the neural and mesenchymal subtypes compared to other subtypes, and associated with the status of several genetic aberrations such as PTEN deletion and wild type IDH1",
                "Knockdown of NUSAP1 revealed its regulation on G2/M progression and cell proliferation (both in vitro and in vivo)"
            ],
            "conclusions": [
                "Study provides new insights and evidence that NUSAP1 over-expression was significantly correlated with progression and prognosis of GBM",
                "Data demonstrate that NUSAP1 could serve as a novel prognostic marker and a potential therapeutic target for GBM"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001A",
        "pmid": 29991527,
        "biomarkerId": "B000019",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "USA"
        ],
        "research": {
            "methods": [
                "qPCR",
                "Western blot",
                "LINC00152 subcellular fractionation and in situ hybridization",
                "MTT and matrigel invasion assays",
                "TCGA data analysis",
                "RNA-seq analysis",
                "LINC00152 structure predictions",
                "Kaplan-Meier method",
                "t-test"
            ],
            "results": [
                "LINC00152 is overexpressed in agressive gliomas",
                "In GBMs, patients who had high expression of LINC00152 had a poor prognosis compared to the patients expressing low level of LINC00152, with a median survival of 11.9 and 15.4 months",
                "LINC00152 expression was also able to separate patients into two distinct prognostic groups in LGGs",
                "LGG patients with high expression of LINC00152 had a median survival of 62.1 months, while the low expressing group had a median survival of 98.2 months",
                "LINC00152 expression controls GBM cell invasion and knockdown of it decreses expression of pro-invasive genes",
                "LINC00152 is not involved in sponging of miRNAs where as LINC00152 stem-loop, M8 is sufficient to promote cell invasion"
            ],
            "conclusions": [
                "Data reveal that LINC00152 and its homolog MIR4435-2HGassociate with aggressive tumors and promote cellular invasion through a mechanism that requires the structural integrity of a hairpin structure",
                "Frequent upregulation of the lncRNA, LINC00152, in GBM and other tumor types combined with its prognostic potential and ability to promote invasion suggests LINC00152 as a potential biomarker and therapeutic target"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001B",
        "pmid": 29991124,
        "biomarkerId": "B00001A",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 45.0,
                "under": 47.0,
                "over": 56.0
            }
        },
        "gender": {
            "male": 56.0,
            "female": 56.0,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Stable transfection of GBP1",
                "Western blot",
                "Real-time PCR",
                "Immunohistochemistry",
                "Cell proliferation assay",
                "Cell invasion and migration",
                "Cell viability assay",
                "X-ray irradiation",
                "Xenograft model",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "In both datasets, GBM tissues exhibited increased mRNA expression of GBP1 gene, its expression level was co-related to PETN deletion and EGFR amplification, and was associated with prognosis of GBM patients",
                "GBP1 overexpression can enhance migration and invasion ability of tumor cells in vitro, and in vivo studies showed that GBP1 can promote tumor proliferation, decrease survival in tumor-bearing mice",
                "GSEA analysis predicted that GBP1 may play its biological roles via toll-like receptor pathway"
            ],
            "conclusions": [
                "This study provides new insights and evidences that high level expression of GBP1 is significantly correlated with progression and prognosis in GBMs",
                "Transfection of GBP1 revealed its regulation on migration and invasiveness of glioma cells, decreasing sensitivity of chemotherapeutic agent, shortening survival of tumor-bearing animals",
                "Data demonstrate that GBP1 may serve as a novel prognostic biomarker and a potential therapeutic target for gliomas"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001C",
        "pmid": 29984907,
        "biomarkerId": "B00001B",
        "sourceIds": [
            "Tissue",
            "Imaging"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Sanger sequencing",
                "Pyrosequencing",
                "MRI",
                "Immunohistochemistry",
                "Random survival forest analysis",
                "LASSO",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model",
                "ROC curve analysis"
            ],
            "results": [
                "Wild-type IDH was present in 89.8% of the adult GBM samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary GBMs, respectively",
                "Age and MGMT promoter methylation were identified as independent prognostic biomarkers, and the TERT promoter mutation status and MGMT promoter methylation status, when combined with other tumor-related factors, generated several different survival subgroups",
                "None of the factors investigated in this study predicted the MGMT promoter status, and MRI-detected necrosis was positively associated with TERT promoter mutations"
            ],
            "conclusions": [
                "MGMT promoter methylation and TERT promoter mutations, combined with MRI-derived and clinical features, revealed different survival subgroups with distinct responses to current treatments, and this information increases the ability to predict the survival of adult primary glioblastoma patient",
                "MRI-detected necrosis often indicates the presence of TERT promoter mutations"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes ",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001D",
        "pmid": 29984907,
        "biomarkerId": "B00001C",
        "sourceIds": [
            "Tissue",
            "Imaging"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Sanger sequencing",
                "Pyrosequencing",
                "MRI",
                "Immunohistochemistry",
                "Random survival forest analysis",
                "LASSO",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model",
                "ROC curve analysis"
            ],
            "results": [
                "Wild-type IDH was present in 89.8% of the adult GBM samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary GBMs, respectively",
                "Age and MGMT promoter methylation were identified as independent prognostic biomarkers, and the TERT promoter mutation status and MGMT promoter methylation status, when combined with other tumor-related factors, generated several different survival subgroups",
                "None of the factors investigated in this study predicted the MGMT promoter status, and MRI-detected necrosis was positively associated with TERT promoter mutations"
            ],
            "conclusions": [
                "MGMT promoter methylation and TERT promoter mutations, combined with MRI-derived and clinical features, revealed different survival subgroups with distinct responses to current treatments, and this information increases the ability to predict the survival of adult primary glioblastoma patient",
                "MRI-detected necrosis often indicates the presence of TERT promoter mutations"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001E",
        "pmid": 29966699,
        "biomarkerId": "B00001D",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": 54.0,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "Brazil",
            "UK"
        ],
        "research": {
            "methods": [
                "Quantitative real time PCR",
                "Gas chromatography-electron impact mass spectrometry",
                "Liquid chromatography-tandem mass spectrometry",
                "TCGA data analysis",
                "ANOVA",
                "Tukey's test",
                "Kruskal-Wallis test",
                "Dunn's post -test",
                "Mann-Whitney test",
                "Log-rank test",
                "Kaplan-Meier method"
            ],
            "results": [
                "Observed significant correlations between high mRNA expression levels and poor patient survival for microsomal PGE synthase 1 (mPGES1) and prostaglandin reductase 1 (PTGR1)",
                "Conversely, high mRNA expression levels for 15-hydroxyprostaglandin dehydrogenase (15-HPGD) were correlated with better patient survival",
                "GBMs had a higher quantity of the prostanoid precursor, arachidonic acid, versus grade II/III tumors and in GBMs a significant positive correlation was found between arachidonic acid and PGE2 content",
                "GBMs also had higher concentrations of TXB2, PGD2, PGE2 and PGF2\u03b1 versus grade II/III tumors",
                "A significant decrease in survival was detected for high versus low PGE2, PGE2 + PGE2 deactivation products (PGEMs) and PGF2\u03b1 in GBM patients"
            ],
            "conclusions": [
                "Data show the potential importance of prostanoid metabolism in the progression towards GBM and provide evidence that higher PGE2 and PGF2\u03b1concentrations in the tumor are correlated with poorer patient survival",
                "Findings highlight the potential importance of the enzymes 15-HPGD and PTGR1 as prognostic biomarkers which could be used to predict survival outcome of patients with GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00001F",
        "pmid": 29966699,
        "biomarkerId": "B00001E",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": 54.0,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "Brazil",
            "UK"
        ],
        "research": {
            "methods": [
                "Quantitative real time PCR",
                "Gas chromatography-electron impact mass spectrometry",
                "Liquid chromatography-tandem mass spectrometry",
                "TCGA data analysis",
                "ANOVA",
                "Tukey's test",
                "Kruskal-Wallis test",
                "Dunn's post -test",
                "Mann-Whitney test",
                "Log-rank test",
                "Kaplan-Meier method"
            ],
            "results": [
                "Observed significant correlations between high mRNA expression levels and poor patient survival for microsomal PGE synthase 1 (mPGES1) and prostaglandin reductase 1 (PTGR1)",
                "Conversely, high mRNA expression levels for 15-hydroxyprostaglandin dehydrogenase (15-HPGD) were correlated with better patient survival",
                "GBMs had a higher quantity of the prostanoid precursor, arachidonic acid, versus grade II/III tumors and in GBMs a significant positive correlation was found between arachidonic acid and PGE2 content",
                "GBMs also had higher concentrations of TXB2, PGD2, PGE2 and PGF2\u03b1 versus grade II/III tumors",
                "A significant decrease in survival was detected for high versus low PGE2, PGE2 + PGE2 deactivation products (PGEMs) and PGF2\u03b1 in GBM patients"
            ],
            "conclusions": [
                "Data show the potential importance of prostanoid metabolism in the progression towards GBM and provide evidence that higher PGE2 and PGF2\u03b1concentrations in the tumor are correlated with poorer patient survival",
                "Findings highlight the potential importance of the enzymes 15-HPGD and PTGR1 as prognostic biomarkers which could be used to predict survival outcome of patients with GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000020",
        "pmid": 29959764,
        "biomarkerId": "B00001F",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Microarray and data analysis",
                "Cox regression analysis",
                "Kaplan-Meier method",
                "Gene ontology"
            ],
            "results": [
                "Analysis revealed 19 lncRNAs with survival time dependency",
                "Out of these, nine were used to construct our survival model via multivariate Cox regression analysis: TP73-AS1, AC078883.3, RP11-944L7.4, HAR1B, RP4-635E18.7, HOTAIR, SAPCD1-AS1, AC104653.1, and RP5-1172N10.2",
                "These genes were enriched with ion binding, transport, cell-cell signaling, plasma membrane parts, and more, and they were mainly related to neuroactive ligand-receptor interaction pathway, calcium signaling pathway, and the mitogen-activated protein kinase signaling pathway"
            ],
            "conclusions": [
                "The nine lncRNAs were a set of biomarkers for the prognosis of patients with GBM, enabling a more accurate prediction of survival and revealing more biological functions"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": "Potential",
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": "Potential"
    },
    {
        "_id": "V000021",
        "pmid": 29952031,
        "biomarkerId": "B000020",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 17.0,
            "max": 80.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Turkey"
        ],
        "research": {
            "methods": [
                "Immunohistochemistry",
                "Mann-Whitney U-test",
                "Chi-square test",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "Overexpression of CA-IX in patients who had progressed in the first 3 months was higher than in those who had progressed after 3 months",
                "The median OS was longer in patients with low levels of CA-IX expression (18 months) compared to patients overexpressing CA-IX (9 months)",
                "There was not a statistically significant difference in median PFS (3.5 vs. 8months) between patients with high or low levels of CA-IX expression",
                "Preoperative Karnofsky performance scale score (KPS) (hazard ratio (HR), 3.703), CA-IX over- expression (HR, 1.967), and incomplete adjuvant temozolomide treatment (HR, 2.241) and gross-total resection (HR, 1.956) were identified as significant prognostic factors for OS"
            ],
            "conclusions": [
                "Findings indicated that CA-IX may be a potential prognostic biomarker in the treatment of GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000022",
        "pmid": 29914265,
        "biomarkerId": "B000021",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 60.0,
                "under": 19.0,
                "over": 21.0
            }
        },
        "gender": {
            "male": 21.0,
            "female": 21.0,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Small interfering RNA transfection",
                "Colony formation assay",
                "Wound healing and transwell assays",
                "Quantitative real-time PCR",
                "Western blot",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model",
                "t-test"
            ],
            "results": [
                "CLEC18B was markedly elevated in both GBM tissues and cells, and exhibited strong inverse correlation with overall survival in GBM patients",
                "CLEC18B was identified as an independent predictor of patient survival",
                "Functionally, knockdown of CLEC18B inhibited the growth, migration, and invasion of GBM cells",
                "Silencing of CLEC18B resulted in downregulation of Wnt/\u03b2-catenin signaling activity"
            ],
            "conclusions": [
                "Findings provide clinical, molecular, and cellular evidence of CLEC18B as a promising prognostic biomarker and therapeutic target for GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000023",
        "pmid": 29901177,
        "biomarkerId": "B000022",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": null,
            "results": [
                "miR-524 were demonstrated to be significantly downregulated in human GBM tissues and cell lines",
                "Functional experiments indicated that restored expression of miR\u2011574 using mimics led to the inhibition of the cell proliferation and invasion of GBM cells respectively",
                "Zinc finger E\u2011box\u2011binding homeobox 1 (ZEB1) may be a target of miR\u2011574 in GBM",
                "ZEB1 was demonstrated to be upregulated and inversely correlated with miR\u2011574 expression in clinical GBM tissues",
                "Overexpression of ZEB1 attenuated the inhibitory effects of miR\u2011574 on the proliferation and invasion of GBM cells"
            ],
            "conclusions": [
                "Results of the present study highlighted the potential tumour inhibitory roles of miR\u2011574 in GBM, thereby indicating that miR\u2011574 may be a novel and efficient therapeutic target for the treatment of patients with GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": null,
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000024",
        "pmid": 29782850,
        "biomarkerId": "B000023",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": 13.0,
            "max": 72.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Immunohistochemitry",
                "RNA extraction and RT-qPCR",
                ". Overexpression and knock-down of HDAC1 in GBM cell line",
                "Western Blot",
                "Cell viability assay",
                "Cell invasion assay",
                "Tumor formation assay",
                "ANOVA"
            ],
            "results": [
                "Protein and mRNA levels of HDAC1 were increased in glioma cell lines and glioma tissues compared to normal glial cell lines and non-neoplastic brain tissues, respectively",
                "HDAC1 knockdown cells displayed decreased proliferation and invasion capabilities, whereas HDAC1 overexpressing GBM cells displayed more proliferation and invasion capabilities in vitro",
                "Knockdown of HDAC1 possibly suppressed the expression of phosphorylated AKT (p-AKT) and phosphorylated ERK (p-ERK) proteins, while overexpression of HDAC1 significantly increased p-AKT and p-ERK protein in GBM cells",
                "Knockdown of HDAC1 repressed subcutaneous tumor growth in vivo, and led to down-regulation of p-AKT and p-ERK protein in U87 MG xenograft tumors"
            ],
            "conclusions": [
                "For the first time, study demonstrated that HDAC1 promotes proliferation and invasion in GBM cells by activating PI3K/AKT and MEK/ERK signaling pathways in vitro and in vivo",
                "These results suggest that HDAC1 may be a novel biomarker and potential therapeutic target in glioblastoma."
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000025",
        "pmid": 29781781,
        "biomarkerId": "B000024",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": null,
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Microarray data processing",
                "ROC curve analysis",
                "Kaplan-Meier curves",
                "Log-rank test",
                "Protein-Protein interaction network and module analysis",
                "Function annotation",
                "Drug target analysis",
                "Cox regression"
            ],
            "results": [
                "A total of 598 genes were identified as significant risk genes for prognosis, such as checkpoint kinase 1, potassium inwardly-rectifying channel, subfamily J, member 6, leukocyte receptor tyrosine kinase and uncharacterized LOC283887",
                "All risk genes for prognosis of HGA were significantly enriched in cell cycle, mitotic as well as mitotic anaphase",
                "The genes in the network module mainly participated in functions such as cell cycle, mitotic cell cycle and cell cycle process",
                "The genes in the network module mainly participated in the pathways such as cell cycle and cell cycle, mitotic",
                "Drug target analysis showed that seven genes were recorded in Drugbank database, and there were as many as 32 drug records of CHEK1"
            ],
            "conclusions": [
                "The prognostic effect of CHEK1 was validated based on the expression profile data of 615 low-grade glioma and GBM samples",
                "Study proposed CHEK1 as prognostic biomarker for HGA"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000026",
        "pmid": 29753008,
        "biomarkerId": "B000025",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Immunohistochemistry",
                "ANOVA",
                "Kaplan-Meier method",
                "Log-rank test"
            ],
            "results": [
                "MCM6 presented high expression and was associated with poor survival",
                "Immunohistochemistry analysis of an independent data set of 423 glioma tissues confirmed the overexpression of MCM6 protein, especially in GBMs with shorter overall survival",
                "A combination of MCM6 overexpression with IDH1 mutation further improved the prediction of the prognosis of GBMs",
                "Patients with IDH1 mutation and low MCM6 expression exhibited the longest survival, whereas those with high MCM6 expression and wild-type IDH1 showed the shortest"
            ],
            "conclusions": [
                "Collectively, observation indicates that MCM6 is a novel potential biomarker for predicting poor prognosis of the patients with glioma"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000027",
        "pmid": 29733521,
        "biomarkerId": "B000026",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": 48.35,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Immunohistochemistry",
                "Pyrosequencing",
                "Migration and invasion assays",
                "ChIP-qPCR assays",
                "IDH mutation assays",
                "Orthotopic implantation",
                "DNA electrophoretic mobility shift assay",
                "qRT-PCR",
                "Western blot",
                "Chromosome conformation capture",
                "ANOVA",
                "KAPLAN-Meier method",
                "Cox regression"
            ],
            "results": [
                "HMGA2 correlates with glioma grade (highest in GBM) and informs poor patient outcome independently",
                "HMGA2 level was not associated with the IDH mutation condition",
                "HMGA2 promotes the migration and invasion phenotypes of GBM cells",
                "HMGA2 binds to the MMP2 gene promoter and is associated with MMP2 promoter histone acetylation",
                "HMGA2 promotes MMP2 gene transcription via an interaction with the histone acetyltransferase GCN5",
                "HMGA2 promotes MMP2 gene transcription via inducing histone acetylation and chromatin conformational changes",
                "HMGA2 promotes MMP2 expression and GBM cell migration and invasion via GCN5",
                "HMGA2 overexpression correlates with high levels of MMP2 in human glioma samples"
            ],
            "conclusions": [
                "Revealed previously unknown mechanisms of gliomagenesis and malignant progression driven by HMGA2 via direct activation of the transcription of the MMP2 gene, the HMGA2/GCN5 epigenetic regulation axis may provide novel targeting site in malignant glioma therapy",
                "Determined that HMGA2 could predict the poor prognosis of glioma patients and that HMGA2 might act as novel subclassification diagnosis factor",
                "Findings suggested that HMGA2 and MMP2 may be promising prognostic markers and potential therapy site in malignant gliomas"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": "Potential",
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": "Potential"
    },
    {
        "_id": "V000028",
        "pmid": 29733521,
        "biomarkerId": "B000027",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": 48.35,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Immunohistochemistry",
                "Pyrosequencing",
                "Migration and invasion assays",
                "ChIP-qPCR assays",
                "IDH mutation assays",
                "Orthotopic implantation",
                "DNA electrophoretic mobility shift assay",
                "qRT-PCR",
                "Western blot",
                "Chromosome conformation capture",
                "ANOVA",
                "KAPLAN-Meier method",
                "Cox regression"
            ],
            "results": [
                "HMGA2 correlates with glioma grade (highest in GBM) and informs poor patient outcome independently",
                "HMGA2 level was not associated with the IDH mutation condition",
                "HMGA2 promotes the migration and invasion phenotypes of GBM cells",
                "HMGA2 binds to the MMP2 gene promoter and is associated with MMP2 promoter histone acetylation",
                "HMGA2 promotes MMP2 gene transcription via an interaction with the histone acetyltransferase GCN5",
                "HMGA2 promotes MMP2 gene transcription via inducing histone acetylation and chromatin conformational changes",
                "HMGA2 promotes MMP2 expression and GBM cell migration and invasion via GCN5",
                "HMGA2 overexpression correlates with high levels of MMP2 in human glioma samples"
            ],
            "conclusions": [
                "Revealed previously unknown mechanisms of gliomagenesis and malignant progression driven by HMGA2 via direct activation of the transcription of the MMP2 gene, the HMGA2/GCN5 epigenetic regulation axis may provide novel targeting site in malignant glioma therapy",
                "Determined that HMGA2 could predict the poor prognosis of glioma patients and that HMGA2 might act as novel subclassification diagnosis factor",
                "Findings suggested that HMGA2 and MMP2 may be promising prognostic markers and potential therapy site in malignant gliomas"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000029",
        "pmid": 29731893,
        "biomarkerId": "B000028",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 30.0,
            "max": 45.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2007.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "RT-PCR",
                "Kaplan-Meier method",
                "Log-rank test",
                "t-test",
                "Student-Newman-Keuls test",
                "Chi-square test",
                "Cox model"
            ],
            "results": [
                "The expression of CDH2 was identified to be strongly associated with glioma grade in the CGGA and Rembrandt datasets",
                "Patients with low CDH2 expression had an improved prognosis and benefited from temozolomide therapy."
            ],
            "conclusions": [
                "The findings revealed that CDH2 may serve as a prognostic and predictive molecular biomarker for the grading and treatment of glioma"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002A",
        "pmid": 29721393,
        "biomarkerId": "B000029",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Immunohistochemistry",
                "ANOVA",
                "Chi-square test",
                "Kaplan\u2013Meier survival curve and log-rank tests",
                "PCA"
            ],
            "results": [
                "IGFBP2 expression was upregulated in high-grade glioma and GBM and downregulated in IDH mutant glioma",
                "Increased IGFBP2 accompanied PTEN loss and EGFR amplification",
                "GFBP2 is related to immunological processes and predominated immunosuppressive activities in GBM",
                "IGFBP2 was correlated with CHI3L1, TNFRSF1A, LGALS1, TIMP1, VEGFA, ANXA1 and LGALS3, which were classic immunosuppressive biomarkers",
                "Higher IGFBP2 expression predicted unfavorable survival for patients with GBM"
            ],
            "conclusions": [
                "Findings implied that IGFBP2 is involved in immunosuppressive activities and is an independent unfavorable prognostic biomarker for patients with GBM",
                "IGFBP2 is a potential immunotherapeutic target for GBM in future clinical trials."
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002B",
        "pmid": 29720725,
        "biomarkerId": "B00002A",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Mus musculus",
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "UK"
        ],
        "research": {
            "methods": [
                "Microarray preparation, hybridization and data analysis",
                "Biotin double pull-down assay",
                "Luciferase assay",
                "Gap closure assay",
                "Migration assays",
                "Knock-down or overexpression of miR-449a, CCND1 and GPR158",
                "Extreme limiting dilution assay",
                "Differentiation assay",
                "RT-PCR",
                "Mouse neurogenesis profiler array",
                "Caspase-3/7 activity assay",
                "Immunohistochemistry",
                "Image analysis",
                "Kaplan-Meier method"
            ],
            "results": [
                "Used a candidate gene approach in mouse models with two complementary brain tumour phenotypes, developing either slow-growing, diffusely infiltrating gliomas or highly proliferative, non-invasive primitive neural tumours",
                "Identified microRNA-449a as most significantly differentially expressed between these two tumour types",
                "miR-449a has a target dependent effect, inhibiting cell growth and migration by downregulation of CCND1 and suppressing neural phenotypes by inhibition of GPR158",
                "GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type GBM",
                "Lower miR-449a and higher GPR158 expression correlates with longer survival of glioma patients"
            ],
            "conclusions": [
                "The correlation of GPR158 expression with molecular subtypes, patient survival and therapy response suggests a possible role of GPR158 as prognostic biomarker in human gliomas"
            ]
        },
        "application": {
            "validated": "Yes",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002C",
        "pmid": 29662659,
        "biomarkerId": "B00002B",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 35.0,
            "max": 87.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Czech Republic"
        ],
        "research": {
            "methods": [
                "PCR",
                "Histological processing and quantification",
                "Immunohistochemistry",
                "Rank correlation",
                "Mann-Whitney U test",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "20 from 52 GBM tumor samples comprised IDH1 R132H mutation",
                "The majority of mutated tumors were classified as secondary glioblastomas (89.9%)",
                "Patients with IDH1 mutated tumors experienced better progression-free survival as well as overall survival compared with wild type tumors",
                "The significantly lower expression of VEGF was observed in GBM with IDH1 mutation than in wild type tumors",
                "No such association was found for microvascular markers",
                "The increased expression of newly-formed microvessels (ratio CD105/CD31) in tumor samples was associated with worse patient's progression-free survival",
                "IDH1 R132H mutation remained positive prognostic factor for OS (HR = 0.433) but not PFS (HR = 0.560) of GBM patients in multivariate analysis"
            ],
            "conclusions": [
                "Results did not prove the hypothesis that angiogenesis in IDH-mutated GBM is caused mainly by IDH mutation-dependent expression of HIF and downstream overexpression of VEGF",
                "Rather than VEGF-mediated angiogenesis, the alternative mechanisms of microvessels formation such as the aberrant activation of MAPK, PI3K, or Notch signaling can play a significant role in our GBM tumors",
                "The combination of pan-endothelial marker together with the marker of active endothelia CD105/endoglin can improve the histological assessment of GBM microvasculature and better predict of patient\u2019s prognosis"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002D",
        "pmid": 29662659,
        "biomarkerId": "B00002C",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 35.0,
            "max": 87.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Czech Republic"
        ],
        "research": {
            "methods": [
                "PCR",
                "Histological processing and quantification",
                "Immunohistochemistry",
                "Rank correlation",
                "Mann-Whitney U test",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "20 from 52 GBM tumor samples comprised IDH1 R132H mutation",
                "The majority of mutated tumors were classified as secondary glioblastomas (89.9%)",
                "Patients with IDH1 mutated tumors experienced better progression-free survival as well as overall survival compared with wild type tumors",
                "The significantly lower expression of VEGF was observed in GBM with IDH1 mutation than in wild type tumors",
                "No such association was found for microvascular markers",
                "The increased expression of newly-formed microvessels (ratio CD105/CD31) in tumor samples was associated with worse patient's progression-free survival",
                "IDH1 R132H mutation remained positive prognostic factor for OS (HR = 0.433) but not PFS (HR = 0.560) of GBM patients in multivariate analysis"
            ],
            "conclusions": [
                "Results did not prove the hypothesis that angiogenesis in IDH-mutated GBM is caused mainly by IDH mutation-dependent expression of HIF and downstream overexpression of VEGF",
                "Rather than VEGF-mediated angiogenesis, the alternative mechanisms of microvessels formation such as the aberrant activation of MAPK, PI3K, or Notch signaling can play a significant role in our GBM tumors",
                "The combination of pan-endothelial marker together with the marker of active endothelia CD105/endoglin can improve the histological assessment of GBM microvasculature and better predict of patient\u2019s prognosis"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002E",
        "pmid": 29644003,
        "biomarkerId": "B00002D",
        "sourceIds": [
            "Cell line",
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "Taiwan"
        ],
        "research": {
            "methods": [
                "siRNA and shRNA transfection",
                "Kaplan-Meier method",
                "Cox model",
                "qRT-PCR",
                "Cell lysate preparation and western blot",
                "ELISA",
                "Immunohistochemistry",
                "Soft agar colony formation assays",
                "Flow cytometry analysis",
                "Cell migration and invasion assays",
                "Orthotopic tumor xenografts",
                "t-test"
            ],
            "results": [
                "PLOD3 mRNA and protein expression were upregulated in glioma tissues compared to normal brain tissues and was morest significant in GBM",
                "PLOD3 overexpression was correlated with negative survival in glioma patients",
                "PLOD3 silencing suppressed cell proliferation and induced G1 phase arrest through p53-independent regulation of the p21 pathway",
                "Inhibition of PLOD3 in glioma cells decreased VEGF expression, migration and invasion by downregulating mesenchymal markers, including Snail and Twist",
                "Knockdown of PLOD3 inhibited HIF-1\u03b1 accumulation via the ERK signaling pathway under hypoxia"
            ],
            "conclusions": [
                "Findings reveal that PLOD3 is a potential therapeutic target in human gliomas and in particular for GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": null,
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V00002F",
        "pmid": 29642484,
        "biomarkerId": "B00002E",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 23.0,
            "max": 83.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": 2007.0,
        "region": [
            "Canada"
        ],
        "research": {
            "methods": [
                "Expectation maximization",
                "Kaplan-Meier method",
                "Reverse transcription and real-time PCR",
                "Log-rank test",
                "Kruskal-Wallis test",
                "Mann-Whitney U test",
                "Cox model"
            ],
            "results": [
                "In GBM, TGF-\u03b2\u2081 and -\u03b2\u2082 levels were 33- and 11-fold higher respectively than in non-tumoral samples",
                "High to moderate expressions of TGF-\u03b2\u2081 significantly conferred a strikingly poorer OS and PFS in newly diagnosed patients",
                "At relapse, neither isoforms had meaningful impact on clinical evolution"
            ],
            "conclusions": [
                "Study demonstrated that TGF-\u03b2\u2081 is the dominant isoform in newly diagnosed GBM rather than the previously acknowledged TGF-\u03b2\u2082",
                "Study is also the first to unveil a significant relationship between TGF-\u03b2\u2081 expression and OS or PFS in newly diagnosed GBM",
                "TGF-\u03b2\u2081 could serve as a prognostic biomarker or target affecting treatment planning and patient follow-up"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000030",
        "pmid": 29642043,
        "biomarkerId": "B00002F",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 60.0,
                "under": 70.0,
                "over": 28.0
            }
        },
        "gender": {
            "male": 28.0,
            "female": 28.0,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Tissue microarray",
                "Immunohistochemistry",
                "Plasmid constructions",
                "Western blot",
                "qRT-PCR",
                "Cell proliferation assay",
                "Patient follow-up",
                "t-test",
                "Wlcoxon rank test",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox regression"
            ],
            "results": [
                "CPEB4 expression was positively related to glioma pathological grade and elevated in GBM",
                "High expression of CPEB4 was associated with significantly poor prognosis, and could be identified as an independent risk factor for overall survival (OS) and progression-free survival (PFS) of GBM patients (hazard ratio (HR)\u202f=\u202f1.730 and HR\u202f=\u202f1.877, respectively)",
                "In vitro studies further showed that downregulation of CPEB4 significantly reduced the growth rate of T98G and U251 cells comparing with the controls"
            ],
            "conclusions": [
                "Study indicated that increased expression of CPEB4 in primary GBM is a novel biomarker for predicting poor outcome of patients and suppression of CPEB4 inhibit tumor cell proliferation, suggesting a potential therapeutic target for GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Yes",
            "predictive": "Potential",
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000031",
        "pmid": 29631594,
        "biomarkerId": "B000030",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 50.0,
                "under": 44.0,
                "over": 52.0
            }
        },
        "gender": {
            "male": 52.0,
            "female": 52.0,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China",
            "Spain"
        ],
        "research": {
            "methods": [
                "RT-PCR",
                "Telomere repeat amplification protocol (TRAP) assay",
                "Western Blot",
                "Cell viability assay",
                "Colony formation assay",
                "Flow cytometric analysis",
                "t-test",
                "Kaplan-Meier curves",
                "Log-rank test",
                "Chi-square test"
            ],
            "results": [
                "The \u03b2 splicing was verified in human gliomas and hTERT+\u03b2 was significantly correlated with higher telomerase activity, higher KPS, larger tumor size, and higher tumor grades",
                "Glioma patients lacking hTERT+\u03b2 expression or telomerase activity showed a significant survival benefit",
                "CX-5461 altered hTERT splicing patterns, leading to an increase of hTERT-\u03b2 transcript and a decrease of hTERT+\u03b2 transcript expression, which inhibits telomerase activity",
                "CX-5461 had cytotoxic effects on GBM cells and caused telomere DNA damage response, induced G2/M arrest and apoptosis"
            ],
            "conclusions": [
                "The hTERT+\u03b2 is verified to be correlated with clinical parameters in gliomas, and could serve as a prognostic marker or possibly therapeutic target for gliomas",
                "CX-5461 can regulate the splicing pattern of hTERT, inhibit telomerase activity, and kill GBM cells"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": "TERT mutations are an up-and-coming biomarker in assessing clinical course, and have potential for clinical use alongside IDH and 1p/19q codeletions",
            "implication": "Assessment of TERT mutation status represents a valuable additive tool to IDH mutation and 1p19q co-deletion in order to refine the World Health Organization (WHO) 2016 classification of gliomas",
            "treatment": "Primary opportunities as a prognostic biomarker"
        },
        "comments": null
    },
    {
        "_id": "V000032",
        "pmid": 29625108,
        "biomarkerId": "B000031",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Plasmid transfection",
                "qRT-PCR",
                "Cell proliferation assay",
                "Trypan blue staining",
                "Western blot",
                "Chromatin immunoprecipitation (CHIP) assay",
                "ANOVA"
            ],
            "results": [
                "Oncogenic miRNA-20a expression increases with WHO grade and is downregulated in IDH1 R132H mutant glioma",
                "IDH1 R132H mutation decreases proliferation, increases cell death, and sensitizes glioma to temozolomide, which is opposed by miR-20a overexpression",
                "IDH1 R132H mutation upregulates HIF-1a, which decreases cMYC and miR-20a expression",
                "miR-20a is directly upregulated by c-MYC in promoter region 1 but not region 2 in GBM cultured cell models"
            ],
            "conclusions": [
                "Elucidating the mechanism underlying oncogenic miR-20a activity establishes its role among well-established signaling pathways (i.e. HIF/c-MYC), and may be a meaningful prognostic biomarker or target for novel therapies, among patients with IDH1-mutant glioma"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000033",
        "pmid": 29614978,
        "biomarkerId": "B000032",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "IV"
        ],
        "whoclass": null,
        "region": [
            "South Africa"
        ],
        "research": {
            "methods": [
                "Feature selection and pathway enrichment analysis",
                "SVM-RFE",
                "Cox model",
                "Kaplan-Meier Method",
                "Log-rank test",
                "STRING database for protein protein interactions"
            ],
            "results": [
                "Survival analysis on TCGA samples not used in feature selection and samples from four GBM subclasses, as well as from an entirely independent study, showed that the 35-gene signature discriminated between the survival groups in all cases and could accurately predict survival irrespective of the subtype",
                "In a multivariate analysis, the signature predicted progression-free and overall survival independently of other factors considered"
            ],
            "conclusions": [
                "Study proposed that the performance of the signature makes it an attractive candidate for further studies to assess its utility as a clinical prognostic and predictive biomarker in GBM patients",
                "Additionally, the signature genes may also be useful therapeutic targets to improve both progression-free and overall survival in GBM patients"
            ]
        },
        "application": {
            "validated": "Yes (GEO)",
            "valcom": "GEO data",
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000034",
        "pmid": 29605294,
        "biomarkerId": "B000033",
        "sourceIds": [
            "Tissue",
            "Cell line"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens",
            "Mus musculus"
        ],
        "age": {
            "min": -1,
            "max": -1,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": 50.0,
                "under": 50.0,
                "over": 50.0
            }
        },
        "gender": {
            "male": 50.0,
            "female": 50.0,
            "other": -1
        },
        "stage": [
            "I",
            "II",
            "III",
            "IV"
        ],
        "whoclass": null,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Cell transfection",
                "Real-time quantitative PCR",
                "Western blot",
                "Cell proliferation assay",
                "Cell cycle analysis",
                "Apoptosis analysis",
                "Cell migration and invasion assays",
                "Xenograft model",
                "t-test",
                "Chi-square test",
                "ANOVA",
                "Kaplan-Meier curves",
                "Cox model"
            ],
            "results": [
                "Found that down-regulation of miR-615 expression occurred in GBM tissues and cells, and was inversely correlated with overall survival, relapse-free survival, WHO grade as well as EGFR expression",
                "miR-615 functions as a tumor suppressor by inhibiting GBM cell proliferation, cell cycle, migration and invasion, and promoting cell apoptosis",
                "In-vivo assay validated the inhibition effect of miR-615 on tumor growth and EGFR expression",
                "miR-615 targeted the 3'-untranslated region (3'-UTR) of EGFR and over-expression of EGFR reversed the inhibition effects of miR-615, while silencing of EGFR aggravated these inhibition effects"
            ],
            "conclusions": [
                "miR-615 plays a tumor suppressor role in GBM cell proliferation, migration and invasion by targeting EGFR expression, and miR-615 may act as a novel biomarker for early diagnosis or therapeutic targets of GBM"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": "Potential",
            "prognosis": "Potential",
            "predictive": null,
            "therapeutic": "Potential"
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": "Potential"
    },
    {
        "_id": "V000035",
        "pmid": 29550762,
        "biomarkerId": "B000034",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 18.0,
            "max": 79.0,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "China"
        ],
        "research": {
            "methods": [
                "Tissue microarray",
                "Immunohistochemistry",
                "Chi-square test",
                "Kaplan-Meier method",
                "Log-rank test"
            ],
            "results": [
                "Found that Hsp27 and p-Hsp27 were mainly expressed in aggressive astrocytic gliomas",
                "Neither Hsp27 nor p-Hsp27 expression was related to survival time for any grade of glioma",
                "p-Hsp27 was mutually exclusive with ATRX loss (ATRX-) and the IDH1R132H mutation, except for one case of AA",
                "Study classified GBMs into three subtypes: ATRX-/IDH1R132H, high p-Hsp27 expression (p-Hsp27+) and none of these three markers",
                "ATRX-/IDH1R132Hshowed the longest median survival (19.6 months)",
                "The prognostic difference between p-Hsp27+ and none of these three markers was significant (15.0 vs 13.1 months, P=0.045)",
                "p-Hsp27+ predicted better sensitivity for standard therapy among GBMs without the IDH1 mutation and ATRX loss (26.3 vs 15.5 months)"
            ],
            "conclusions": [
                "p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression, for evaluating prognosis and for guidance for adjuvant therapy"
            ]
        },
        "application": {
            "validated": "No",
            "valcom": null,
            "diagnosis": null,
            "prognosis": "Potential",
            "predictive": "Potential",
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    },
    {
        "_id": "V000036",
        "pmid": 29523123,
        "biomarkerId": "B000035",
        "sourceIds": [
            "Tissue"
        ],
        "samples": "TODO",
        "species": [
            "Homo Sapiens"
        ],
        "age": {
            "min": 2.6,
            "max": 78.5,
            "med": -1,
            "avg": -1,
            "sd": -1,
            "range": {
                "cutoff": -1,
                "under": -1,
                "over": -1
            }
        },
        "gender": {
            "male": -1,
            "female": -1,
            "other": -1
        },
        "stage": [
            "II",
            "III",
            "IV"
        ],
        "whoclass": 2016.0,
        "region": [
            "Denmark"
        ],
        "research": {
            "methods": [
                "In vitro culturing of spheroids",
                "Immunohistochemistry",
                "Immunofluorescence and automated quantitative image analysis",
                "Confocal microscopy",
                "Proximity ligation assay",
                "Immunoprecipitation",
                "TCGA research network",
                "ANOVA",
                "Kaplan-Meier method",
                "Log-rank test",
                "Cox model"
            ],
            "results": [
                "The expression of CD63 was widely distributed in astrocytomas with a significantly increased level in GBMs",
                "CD63 levels did not significantly correlate with patient survival at a protein level, and CD63 did not augment the prognostic significance of TIMP-1",
                "Up to 38% of the CD63+ cells expressed Iba1, however, Iba1 did not appear to impact the prognostic value of CD63",
                "A significant correlation was found between TIMP-1 and CD63, and the TIMP-1 and CD63 proteins were co-expressed at the cellular level and located in close molecular proximity, suggesting that TIMP-1 and CD63 could be co-players in GBMs",
                "Some TIMP-1+ cells expressed CD133 and Sox2"
            ],
            "conclusions": [
                "The present study suggests that CD63 is highly expressed in GBMs and that TIMP-1 and CD63 interact",
                "CD63 does not add to the prognostic value of TIMP-1",
                "Co-expression of TIMP-1 and stem cell markers as well as the wide expression of CD63 might suggest a role for TIMP-1 and CD63 in glioblastoma stemness"
            ]
        },
        "application": {
            "validated": "Yes (TCGA)",
            "valcom": "TCGA data",
            "diagnosis": null,
            "prognosis": "No",
            "predictive": null,
            "therapeutic": null
        },
        "clinical": {
            "relevance": null,
            "implication": null,
            "treatment": null
        },
        "comments": null
    }
]